BioNTech SE - ADR Aktie News

PHILADELPHIA--(BUSINESS WIRE)--The University of Pennsylvania (“Penn”), BioNTech SE (“BioNTech”), and OUP (Osage University Partners) announced the launch of the $50 million Penn-BioNTech Innovative Therapeutics Seed Fund (“PxB Fund”), a dedicated venture capital fund focused on early-stage life science companies originating from Penn. The joint effort will provide additional fuel to advance Pe...

MAINZ, Germany, December 18, 2025 – BioNTech SE (Nasdaq: BNTX, “BioNTech”, or “the Company”) today announced the closing of its acquisition of CureVac N.V. (Nasdaq: CVAC, “CureVac”) and that the subsequent offering period (the “Subsequent Offering Period”) of the exchange offer (the “Offer”) for all outstanding shares of CureVac expired today at 12:01 a.m. Eastern Time. With the successful acqu...

BioNTech (BNTX) maintains a "Strong Buy" rating, driven by positive phase 3 data for gotistobart in 2nd-line squamous NSCLC patients. BNTX's gotistobart delivered a 63.1% 12-month OS rate versus 30.3% for docetaxel, reducing risk of death by 54%. Upcoming pivotal phase 3 PRESERVE-003 data in 2026 and expansion into ovarian and prostate cancers offer significant pipeline catalysts.

Global interim Phase 2 data in locally advanced/metastatic triple-negative breast cancer (”TNBC”) show encouraging antitumor activity for investigational therapy pumitamig (BNT327/BMS986545) plus chemotherapy in first- and second-line patients Pumitamig plus chemotherapy achieved confirmed objective response rate (cORR) of 61.5%, unconfirmed ORR (uORR) of 71.8% and disease control rate (DCR) of...

Gotistobart demonstrated a clinically meaningful overall survival benefit compared to standard chemotherapy and a manageable safety profile in sqNSCLC

The minimum condition for the offer has been satisfied, with 184,071,410 shares of CureVac, representing approximately 81.74% of CureVac's issued and outstanding shares, tendered prior to the expiration of the initial offering period The subsequent offering period has commenced and will expire at 12:01 a.m. Eastern Time on Thursday, December 18, 2025   MAINZ, Germany, December 3, 2025 – BioNTec...

A report that vaccine approvals could be set to get stricter is pressuring shares of major vaccine makers.

Memo also reportedly mentions vaccines for flu and pneumonia.